NCT05339529 Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
| NCT ID | NCT05339529 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing Medical University |
| Condition | Acute Aortic Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2022-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.
Eligibility Criteria
Inclusion Criteria: * The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset; * Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled. * The patients' age between 18 \~90 years old. * Agree to participate in the study and sign the informed consent. Exclusion Criteria: * Patients allergic to Thymosin α1; * Lactating women and pregnant women; * Patients with mental diseases, drug and alcohol dependence; * Refuse to participate in this study and refuse to sign the informed consent.
Contact & Investigator
Hong Liu
PRINCIPAL INVESTIGATOR
Nanjing Medical University
Frequently Asked Questions
Who can join the NCT05339529 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Acute Aortic Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05339529 currently recruiting?
Yes, NCT05339529 is actively recruiting participants. Contact the research team at DR.HONGLIU@FOXMAIL.COM for enrollment information.
Where is the NCT05339529 trial being conducted?
This trial is being conducted at Bengbu, China, Guangzhou, China, Nanjing, China, Nanjing, China and 11 additional locations.
Who is sponsoring the NCT05339529 clinical trial?
NCT05339529 is sponsored by Nanjing Medical University. The principal investigator is Hong Liu at Nanjing Medical University. The trial plans to enroll 330 participants.